✦ LIBER ✦

Trametinib for patients with advanced melanoma

✍ Scribed by Shigeo Masuda; Juan Carlos Izpisua Belmonte

Book ID: 119609046
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 35 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70419-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Trametinib for patients with advanced me

Trametinib for patients with advanced melanoma – Authors' reply

✍ Gerald S Falchook; Christopher Moy; Douglas J DeMarini 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 45 KB

Activity of the oral MEK inhibitor trame

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

✍ Gerald S Falchook; Karl D Lewis; Jeffrey R Infante; Michael S Gordon; Nicholas J 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 225 KB

Dabrafenib and Trametinib, Alone and in

Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma

✍ Menzies, A. M.; Long, G. V. 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 348 KB

An elderly patient with advanced locoreg

An elderly patient with advanced locoregional melanoma

✍ R. Gennari; S.H. Stoldt; A. Testori; J.G. Geraghty 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 172 KB

Safety and efficacy of arsenic trioxide

Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma

✍ Ahmad A. Tarhini; John M. Kirkwood; Hussein Tawbi; William E. Gooding; Mohammed 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 2 views

## Abstract ## BACKGROUND. Arsenic trioxide (ATO) cytotoxicity and apoptosis induction has been demonstrated with numerous cancer cell lines, including human melanoma. ## METHODS. A second‐line, phase 2, single‐arm study of ATO was conducted in patients with inoperable American Joint Committee o

Biochemotherapy for advanced melanoma

✍ Ulrich Keilholz; Martin E. Gore 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 72 KB